Metastatic recurrence of 17-years relapse-free melanoma during anti-TNFa therapy

Abstract

Tumor-necrosis-factor-alpha (TNFa) is an innate cytokine involved in regulating inflammation, immunity, tumorigenesis, and apoptosis. TNFa inhibitors became a powerful tool in the treatment of auto-immune inflammatory diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis and psoriasis. Known side effects of TNFa inhibitors range from infections to malignancies [1].

We report a male patient who was in 1998 at age 36 diagnosed with amelanotic melanoma of the leg, Breslow thickness 11.0 mm, no ulceration.

This article is protected by copyright. All rights reserved.

http://ift.tt/2lau65Y